Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites
Sho Iketani, Seo Jung Hong, Jenny Sheng, et al.
Cell Host & Microbe (2022) Vol. 30, Iss. 10, pp. 1354-1362.e6
Open Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
Sho Iketani, Hiroshi Mohri, Bruce Culbertson, et al.
Nature (2022) Vol. 613, Iss. 7944, pp. 558-564
Open Access | Times Cited: 329
Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir
Yanmei Hu, Eric M. Lewandowski, Haozhou Tan, et al.
ACS Central Science (2023) Vol. 9, Iss. 8, pp. 1658-1669
Open Access | Times Cited: 220
Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease
G.D. Noske, Ellen de Souza Silva, Mariana Ortiz de Godoy, et al.
Journal of Biological Chemistry (2023) Vol. 299, Iss. 3, pp. 103004-103004
Open Access | Times Cited: 83
Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance
Jonathan Daniel Ip, Allen Wing‐Ho Chu, Wan-Mui Chan, et al.
EBioMedicine (2023) Vol. 91, pp. 104559-104559
Open Access | Times Cited: 77
Fitness effects of mutations to SARS-CoV-2 proteins
Jesse D. Bloom, Richard A. Neher
Virus Evolution (2023) Vol. 9, Iss. 2
Open Access | Times Cited: 77
Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China
Liyan Yang, Zhonglei Wang
European Journal of Medicinal Chemistry (2023) Vol. 257, pp. 115503-115503
Open Access | Times Cited: 65
In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir
Maki Kiso, Seiya Yamayoshi, Shun Iida, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 46
Rapid resistance profiling of SARS-CoV-2 protease inhibitors
Seyed Arad Moghadasi, Rayhan G. Biswas, Daniel A. Harki, et al.
npj Antimicrobials and Resistance (2023) Vol. 1, Iss. 1
Open Access | Times Cited: 33
Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics
Daniele Focosi, Scott A. McConnell, Shmuel Shoham, et al.
International Journal of Antimicrobial Agents (2023) Vol. 61, Iss. 2, pp. 106708-106708
Open Access | Times Cited: 32
Fitness effects of mutations to SARS-CoV-2 proteins
Jesse D. Bloom, Richard A. Neher
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 32
In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir
Maki Kiso, Yuri Furusawa, Ryuta Uraki, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 32
A yeast-based system to study SARS-CoV-2 Mpro structure and to identify nirmatrelvir resistant mutations
Jin Ou, Eric M. Lewandowski, Yanmei Hu, et al.
PLoS Pathogens (2023) Vol. 19, Iss. 8, pp. e1011592-e1011592
Open Access | Times Cited: 25
Large library docking for novel SARS‐CoV‐2 main protease non‐covalent and covalent inhibitors
Elissa A. Fink, Conner Bardine, Stefan Gahbauer, et al.
Protein Science (2023) Vol. 32, Iss. 8
Open Access | Times Cited: 24
Resistance mechanisms of SARS-CoV-2 3CLpro to the non-covalent inhibitor WU-04
Lijing Zhang, Xuping Xie, Hannan Luo, et al.
Cell Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 13
SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs
Sho Iketani, David D. Ho
Cell chemical biology (2024) Vol. 31, Iss. 4, pp. 632-657
Open Access | Times Cited: 13
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 13
Development of small molecule non-covalent coronavirus 3CL protease inhibitors from DNA-encoded chemical library screening
Hengrui Liu, Arie Zask, F. Forouhar, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 2
The impact of SARS-CoV-2 3CL protease mutations on nirmatrelvir inhibitory efficiency. Computational insights into potential resistance mechanisms
Carlos A. Ramos‐Guzmán, Milorad Andjelkovic, Kirill Zinovjev, et al.
Chemical Science (2023) Vol. 14, Iss. 10, pp. 2686-2697
Open Access | Times Cited: 23
Study of key residues in MERS-CoV and SARS-CoV-2 main proteases for resistance against clinically applied inhibitors nirmatrelvir and ensitrelvir
Laura Krismer, Helge Schöppe, Stefanie Rauch, et al.
npj Viruses (2024) Vol. 2, Iss. 1
Open Access | Times Cited: 6
Natural Flavonoid Derivatives Have Pan-Coronavirus Antiviral Activity
Mattia Mori, Deborah Quaglio, Andrea Calcaterra, et al.
Microorganisms (2023) Vol. 11, Iss. 2, pp. 314-314
Open Access | Times Cited: 11
SARS-CoV-2 main protease cleaves MAGED2 to antagonize host antiviral defense
Xiaohui Ju, Ziqiao Wang, Pengcheng Wang, et al.
mBio (2023)
Open Access | Times Cited: 11
A multiplex method for rapidly identifying viral protease inhibitors
Seo Jung Hong, Samuel J. Resnick, Sho Iketani, et al.
Molecular Systems Biology (2025) Vol. 21, Iss. 2, pp. 158-172
Closed Access
Exploring Possible Drug-Resistant Variants of SARS-CoV-2 Main Protease (Mpro) with Noncovalent Preclinical Candidate, Mpro61
Jessica R. Kenneson, Christina Papini, Su Tang, et al.
ACS Bio & Med Chem Au (2025)
Open Access
Potent antiviral activity of simnotrelvir against key epidemic SARS-CoV-2 variants with a high resistance barrier
Liwei Zhao, Chuang Li, Mengyu Wang, et al.
Antimicrobial Agents and Chemotherapy (2025)
Open Access
Carrimycin exhibited broad spectrum inhibitory activities against coronaviruses replication through down-regulating host factor TMEM41B
Kun Wang, Huiqiang Wang, Ge Yang, et al.
Acta Pharmacologica Sinica (2025)
Closed Access
Page 1 - Next Page

Scroll to top